Exhibit 99.1

RADIATION THERAPY SERVICES HOLDINGS, INC.

INFORMATION RELEASE

RADIATION THERAPY SERVICES REPORTS SECOND QUARTER 2011 FINANCIAL

RESULTS

Second Quarter 2011 Highlights:

·      Domestic same practice therapy revenue increased 4.7% versus same period in prior year

·      Domestic same practice RVUs per day increased 12.3% versus same period in prior year

·      Recent acquisition of Medical Developers, LLC exceeding expectations

·      Total Company Pro Forma Adjusted EBITDA was $30.0 million

FORT MYERS, FL, August 15, 2011 — Radiation Therapy Services, Inc, a leading operator of radiation therapy centers, today announced financial results for the second quarter ended June 30, 2011.

Total revenue for the second quarter was $162.3 million, an increase of 20.3% compared to $134.9 million in revenue in the same quarter of 2010. The increase in revenue was principally due to revenue from the May 2010 acquisition of the Myrtle Beach, S.C. physician practices and the March 2011 acquisition of Medical Developers, LLC (Medical Developers), which operates 26 physician practices in Latin America, of $5.1 million and $16.7 million, respectively.

Domestic same practice therapy revenue increased 4.7% from the second quarter of 2010 principally as a result of a mix shift towards more clinically sophisticated radiation oncology services, which resulted in an increase in Relative Value Units (“RVUs”), partially offset by a reduction in the conversion factor for fiscal year 2011.

Total RVUs per day at domestic freestanding centers increased 14.3% in the second quarter versus the same period of the prior year principally as a result of an increase in RVU values heading into 2011 and a mix shift towards more clinically sophisticated radiation oncology services.

Adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation and other non-cash and pro forma items (“Pro Forma Adjusted EBITDA”) increased 3.5% in the second quarter of 2011 to $30.0 million, or 18.5% of pro forma total revenue, from $29.0 million, or 20.9% of total revenue, in the second quarter of 2010. EBITDA margins declined in the quarter versus the previous year due primarily to investments made to strengthen the Company’s infrastructure in the areas of management, marketing, information technology, electronic health records and other initiatives. A reconciliation of net loss attributable to Radiation Therapy Services Holdings, Inc. shareholder determined in accordance with generally accepted accounting principles to Pro Forma Adjusted EBITDA and total revenues determined in accordance with generally accepted accounting principles to total pro forma revenues for the quarters ended June 30, 2011 and 2010 is included in the attached supplemental information.

Income tax expense in the second quarter of 2011 was $3.3 million, compared to an income tax benefit of $4.5 million in the second quarter of 2010.  The Company’s tax expense increased primarily due to the increase in valuation allowance related to deductions attributable to U.S. and certain state non-reversing deferred tax liabilities and foreign tax expense associated with the Medical Developers subsidiaries acquired during the current year. The net loss for the second quarter of 2011 was $4.8 million, compared to a net loss of $8.1 million in the second quarter of 2010.  In the second quarter of 2010, Radiation Therapy recorded pre-tax charges of $10.9 million for early extinguishment of debt and $1.9 million for the loss on sale of assets of a radiation treatment center.

Six Month Results

Total revenue for the six months ended June 30, 2011 was $318.8 million, an increase of 18.3% compared to $269.4 million in revenue in the prior year period. The increase in revenue was principally due to revenue from the May 2010 acquisition of the Myrtle Beach, S.C. physician practices and the March 2011 acquisition of Medical Developers which operates 26 physician practices in Latin America, of $15.0 million and $21.9 million, respectively.

Same practice therapy revenue increased 3.0% compared to first six months of 2010 principally as a result of a mix shift towards more clinically sophisticated radiation oncology services, which resulted in an increase in Relative Value Units (“RVUs”), partially offset by a reduction in the conversion factor for fiscal year 2011.

Total RVUs per day at domestic freestanding centers increased 14.5% in the first six months of 2011 versus the same period of the prior year principally as a result of an increase in RVU values heading into 2011 and a mix shift towards more clinically sophisticated radiation oncology services.

Adjusted earnings before interest, taxes, depreciation, amortization, stock-based compensation and other non-cash and pro forma items (“Pro Forma Adjusted EBITDA”) increased 9.0% in the first six months of 2011 to $62.0 million, or 18.8% of pro forma total revenue, from $56.9 million, or 20.2% of pro forma total revenue, in the prior year period. EBITDA margins declined in the first six months of 2011 versus the previous year due primarily to investments made to strengthen the Company’s infrastructure in the areas of management, marketing, information technology, electronic health records and other initiatives.  A reconciliation of net loss attributable to Radiation Therapy Services Holdings, Inc. shareholder determined in accordance with generally accepted accounting principles to Pro Forma Adjusted EBITDA and total revenues determined in accordance with generally accepted accounting principles to total pro forma revenues for the six months ended June 30, 2011 and 2010 is included in the attached supplemental information.

Income tax expense in the first six months of 2011 was $5.8 million, compared to an income tax benefit of $5.2 million in the prior year period.  The Company’s tax expense increased primarily due to the increase in valuation allowance related to deductions attributable to U.S. and certain state non-reversing deferred tax liabilities and foreign tax expense associated with the Medical Developers subsidiaries acquired during the current year. The net loss for the first six months of 2011 was $7.9 million, compared to a net loss of $9.1 million in prior year period 2010.  In the first six months of 2010, Radiation Therapy recorded pre-tax charges of $10.9 million for early extinguishment of debt and $1.9 million for the loss on sale of assets of a radiation treatment center.

Dr. Daniel Dosoretz, President and Chief Executive Officer, said, “Despite the continued challenging environment in healthcare, we are beginning to see improvements in volume levels in our same practice centers, which includes stabilization in our Florida and Nevada markets.  The 12.3% increase in same practice RVUs per day reflects these volume improvements as well as our continuing mix shift towards more clinically sophisticated radiation oncology services.

“We remain very excited about the growth opportunity at Medical Developers, which provides us with a strong foothold in the rapidly growing Latin American market.  This is a very robust market and the acquisition is tracking ahead of plan. Going forward, we will continue to execute on our strategy to develop de novo centers and acquire additional centers, both in this attractive market, as well as domestic markets,” concluded Dr. Dosoretz

Conference Call

Management will host a conference call Monday August 15, 2011 at 1:00 p.m. EDT to discuss financial results, other developments and business conditions. The dial-in numbers are (877) 407-0789 for domestic callers and (201) 689-8562 for international callers.  In addition, a telephonic replay of the call will be available until August 29, 2011.  The replay dial-in numbers are (877) 870-5176 for domestic callers and (858) 384-5517 for international callers.  Please use the conference ID number 375867 to access the replay.

About Radiation Therapy Services Holdings , Inc.

Radiation Therapy Services Holdings, Inc., which operates radiation treatment centers primarily under the name 21st Century Oncology, is a provider of advanced radiation therapy services to cancer patients. In total, the Company operates 119 treatment centers, including 92 centers located in 16 U.S. states, 26 centers located in six countries in Latin America and 1 center located in India.  The Company is headquartered in Fort Myers, Florida.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Act of 1934, as amended.  These statements are based on management’s current expectations or beliefs about the Company’s future plans, expectations and objectives, including, but not limited to, the Company’s expected financial results and estimates for 2011.  These forward-looking statements are not historical facts and are subject to risks and uncertainties that could cause the actual results to differ materially from those projected in these forward-looking statements including, but not limited to the Company’s actual financial results and those risk factors that may be described from time to time in the Company’s filings with the Securities and Exchange Commission.  Readers of this release are cautioned not to place undue reliance on forward-looking statements contained herein, which speak only as of the date stated, or if no date is stated, as of the date of this press release. The Company undertakes no obligation to publicly update or revise the forward-looking statements contained herein to reflect changed events or circumstances after the date of this release, unless required by law.

Financial Tables on Following Pages

RADIATION THERAPY SERVICES HOLDINGS, INC.

CONDENSED CONSOLIDATED BALANCE SHEETS

(in thousands, except share and per share amounts)

RADIATION THERAPY SERVICES HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands)

(unaudited)

RADIATION THERAPY SERVICES HOLDINGS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

(in thousands)

(unaudited)

RADIATION THERAPY SERVICES HOLDINGS, INC.

Supplemental Financial Information (Unaudited)

Reconciliation of Pro-forma Revenue and Adjusted EBITDA to Net Loss Attributable

to Radiation Therapy Services Holdings, Inc. Shareholder

(1) Pro-forma Adjusted EBITDA is defined as income (loss) before interest expense (net of interest income), income taxes, depreciation and amortization, foreign currency derivative contract loss, gain on fair value adjustment of previously held equity investment, management fees from our sponsor, non-cash expenses including costs relating to stock compensation, amortization of straight-line rent and amortization of capital expenditures relating to repairs and maintenance, sale-lease back adjustments, acquisition-related costs, other expenses including loss on sale of assets, severance payments related to termination of employee staff reductions and tail premiums on termed physicians, litigation settlements with physicians, costs associated with the provision for income taxes and pro-forma full period effect of acquisition EBITDA.

(a) Pro-forma amounts related to adjustments to total revenues and Pro-forma Adjusted EBITDA to reflect the full period effect of our acquisition completed during 2010 and 2011, including the purchase of the South Carolina physician practices in May 2010 and the purchase of Medical Developers’ phycian practices in March 2011.  The adjustments reflect the impact to our total revenues and Pro-forma Adjusted EBITDA as if the acquisitions had occurred at the beginning of the year.

(b) Management fees are fees paid to our sponsor, Vestar Capital Partners.

(c) Non-cash expenses including costs relating to stock compensation, amortization of straight-line rent and amortization of capital expenditures relating to warranty arrangements amortized to repairs and maintenance.

(d) Sale-lease back adjustments relates to the adjustment of benefit derived from the classification of operating leases as finance obligations reflecting a reclassification of interest expense and depreciation and amortization expense as rent expense.

(e) Acquisition related costs associated with the adoption of ASC 805, Business Combinations, requiring prior capitalized costs be expensed, including professional fees and due diligence costs relating to the acquisition of physician practices.

(f) Other expenses include loss on sale of assets, severance payments related to termination of employee staff reductions and tail premiums paid on terminated physicians.

(g) Litigation settlement relates to costs associated with the termination of physicians during 2010 and 2011 as a result of the cost savings plans implemented in the fourth quarter of 2009.

(h) Expenses related to the costs associated with process improvements in the provision for income taxes.

We believe the Pro-forma Adjusted EBITDA provides useful information about our financial performance to investors, lenders, financial analysts and rating agencies since these groups have historically used EBITDA-related measures in the healthcare industry, along with other measures, to estimate the value of a company, to make informed investment decisions, to evaluate a company’s leverage capacity and its ability to meet its debt service requirements.  Pro-forma Adjusted EBITDA eliminates the uneven effect of non-cash depreciation of tangibles assets and amortization of intangible assets, much of which results from acquisitions accounted for under the purchase method of accounting.  Pro-forma Adjusted EBITDA is also used by us to measure individual performance for incentive compensation purposes and as an analytical indicator for purposes of allocating resources to our operating business and assessing their performance, both internally and relative to our peers, as well as to evaluate the performance of our operating management teams, and for purposes in the calculation of debt covenants and related disclosures.

Pro-forma Adjusted EBITDA is not intended as a substitute for net income (loss) attributable to Radiation Therapy Services Holdings, Inc. shareholder, operating cash flows or other cash flow data determined in accordance with accounting principles generally accepted in the United States. Due to varying methods of calculation, Pro-forma Adjusted EBITDA as presented may not be comparable to similarly titled measures of other companies.

RADIATION THERAPY SERVICES HOLDINGS, INC.

KEY OPERATING STATISTICS

(unaudited)

* includes full period operating statistics, including period prior to our acquisition

###